Biology Reference
In-Depth Information
106. Hofmann-Lehmann R, Vlasak J, Rasmussen RA,
et al
. (2002)
Postnatal pre- and postexposure passive immunization strategies: pro-
tection of neonatal macaques against oral simian-human immunodefi-
ciency virus challenge.
J Med Primatol
31
: 109-119.
107. Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA,
et al
.
(2001) Protection of neonatal macaques against experimental SHIV
infection by human neutralizing monoclonal antibodies.
Transfus Clin
Biol
8
: 350-358.
108. Safrit JT, Ruprecht R, Ferrantelli F,
et al
. (2004) Immunoprophylaxis
to prevent mother-to-child transmission of HIV-1.
J Acquir Immune
Defic Syndr
35
: 169-177.
109. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA,
et al
. (2003)
Post-exposure prophylaxis with human monoclonal antibodies pre-
vented SHIV89.6P infection or disease in neonatal macaques.
AIDS
17
: 301-309.
110. Ferrantelli F, Kitabwalla M, Rasmussen RA,
et al
. (2004) Potent cross-
group neutralization of primary human immunodeficiency virus isolates
with monoclonal antibodies — implications for acquired immunodefi-
ciency syndrome vaccine.
J Infect Dis
189
: 71-74.
111. Ho DD, Sarngadharan MG, Hirsch MS,
et al
. (1987) Human immun-
odeficiency virus neutralizing antibodies recognize several conserved
domains on the envelope glycoproteins.
J Virol
61
: 2024-2028.
112. Montefiori DC, Pantaleo G, Fink LM,
et al
. (1996) Neutralizing and
infection-enhancing antibody responses to human immunodeficiency
virus type 1 in long-term nonprogressors.
J Infect Dis
173
: 60-67.
113. Moog C, Fleury HJ, Pellegrin I,
et al
. (1997) Autologous and het-
erologous neutralizing antibody responses following initial serocon-
version in human immunodeficiency virus type 1-infected individuals.
J Virol
71
: 3734-3741.
114. Moore JP, Sattentau QJ, Wyatt R, Sodroski J. (1994) Probing the
structure of the human immunodeficiency virus surface glycoprotein
gp120 with a panel of monoclonal antibodies.
J Virol
68
: 469-484.
115. Pilgrim AK, Pantaleo G, Cohen OJ,
et al
. (1997) Neutralizing anti-
body responses to human immunodeficiency virus type 1 in primary
infection and long-term-nonprogressive infection.
J Infect Dis
176
:
924-932.
116. Wrin T, Crawford L, Sawyer L,
et al
. (1994) Neutralizing antibody
responses to autologous and heterologous isolates of human immun-
odeficiency virus.
J Acquir Immune Defic Syndr
7
: 211-219.
